Peptide Knowledge Center
Research progress of liraglutide in the treatment of overweight
Obesity is a chronic metabolic disease caused by the interaction of environmental, genetic and other factors. Obesity has become a common disease in the United States.
In 2012, more than one-third of Americans were identified as obese. However, in 1990, the obesity rate in the United States was less than 15%. For obese people, especially those with type 2 diabetes, it is recommended to lose weight. Proper weight loss (5%~10%) can improve blood sugar control and reduce weight loss.
Other cardiovascular metabolic risk factors and complications. It is usually difficult to achieve and maintain weight loss only through lifestyle intervention.The reason is the disorder of hormone secretion, metabolism and neural function related to multiple obesity.
Liraglutide is an analog of human hyperinsulinemic peptide-1 (GLP-1). It can stimulate insulin secretion in a glucose concentration dependent mode, reduce excessive glucagon secretion in a glucose concentration dependent mode, delay gastric emptying, and reduce food intake through central appetite control; It can also enhance the sensitivity of peripheral tissues to insulin, thereby reducing postprandial blood glucose and body weight. Therefore, in clinic, it can be used alone or combined with other oral hypoglycemic agents to control body weight or treat type 2 diabetes.
Relationship between Liraglutide and type II diabetes mellitus
There are more than 1.9 billion overweight adults and 600 million obese adults in the world. It is very important to formulate safe and effective long-term treatment and weight loss programs. In the United States, there are mainly five kinds of weight loss drugs approved by FDA for listing, namely orlistat, locaserin, naltrexone bupropion, fentanyl topiramate and liraglutide. Liraglutide is a new weight loss drug listed in recent years, and the research on the comparison of the effects and side effects of weight loss drugs has attracted more and more attention. Body fat will increase at age 70 and increase with age. Over 60 years old, the risk of weight-loss surgery exceeds the benefits, and more and more elderly people with type II diabetes.
A randomized controlled experiment reported in the New England Journal showed that liraglutide could significantly reduce weight and improve metabolism in obese and overweight patients with dyslipidemia and hypertension. At the same time, liraglutide could improve blood glucose control, fasting insulin concentration, cardiac metabolic markers and quality of life. Because of its dual benefits of controlling body weight and blood sugar, it is a unique treatment for obese and type 2 diabetic patients.
Email: [email protected]
Address: 774 Nathan Road,Kowloon Peninsula ,999077,HongKong